TY - JOUR
T1 - Copper(II) complexes of indolo[2,3-c]quinoline-derived Schiff bases
T2 - Insight into the mechanism of their antiproliferative activity
AU - Bacher, Felix
AU - Madejski, Christian
AU - Kuznetcova, Irina
AU - Dömötör, Orsolya
AU - Gyurcsik, Béla
AU - Nafaee, Zeyad H.
AU - Igaz, Nóra
AU - Bocz, Csenge
AU - Péntek, Bálint
AU - Kiricsi, Mónika
AU - Raptova, Petra
AU - Stoica, Alexandru-Constantin
AU - Hejl, Michaela
AU - Jakupec, Michael A.
AU - Alfadul, Samah Mutasim
AU - Babak, Maria V.
AU - Rapta, Peter
AU - Reynisson, Jóhannes
AU - Sindlerova, Lenka
AU - Enyedy, Éva A.
AU - Hamel, Ernest
AU - Arion, Vladimir B.
PY - 2026/4/21
Y1 - 2026/4/21
N2 - Indoloquinolines are potent anticancer agents, but their poor aqueous solubility prevents clinical development. Indoloquinoline-based metal complexes offer an opportunity to circumvent this drawback. A series of new indolo[2,3-c]quinoline derivatives HL1–HL8 and their copper(II) complexes were synthesized, comprehensively characterized and tested for antiproliferative activity against MDA-MB-231, MCF-7, MCF-7 KCR, A549 and DU-145 cancer cells and compared to known isomeric indolo[3,2-c]quinolines (HL11–HL14 and 11–14). The Cu(II) complexes were generally as active, or slightly more so, than the proligands. Lead compounds HL8 and 8 showed superior anticancer activity compared to isomers HL14 and 14, respectively. Complex 8 was superior to HL8 in ROS generation in A549 cells, induced mitochondrial dysfunction as evidenced by JC-1 staining, induced lactate dehydrogenase release in medium, inhibited DNA synthesis and triggered apoptosis. DNA-binding studies, supported by molecular docking calculations, showed strong affinity of the compounds for double stranded DNA, to which they bind by intercalation. © 2026 The Authors.
AB - Indoloquinolines are potent anticancer agents, but their poor aqueous solubility prevents clinical development. Indoloquinoline-based metal complexes offer an opportunity to circumvent this drawback. A series of new indolo[2,3-c]quinoline derivatives HL1–HL8 and their copper(II) complexes were synthesized, comprehensively characterized and tested for antiproliferative activity against MDA-MB-231, MCF-7, MCF-7 KCR, A549 and DU-145 cancer cells and compared to known isomeric indolo[3,2-c]quinolines (HL11–HL14 and 11–14). The Cu(II) complexes were generally as active, or slightly more so, than the proligands. Lead compounds HL8 and 8 showed superior anticancer activity compared to isomers HL14 and 14, respectively. Complex 8 was superior to HL8 in ROS generation in A549 cells, induced mitochondrial dysfunction as evidenced by JC-1 staining, induced lactate dehydrogenase release in medium, inhibited DNA synthesis and triggered apoptosis. DNA-binding studies, supported by molecular docking calculations, showed strong affinity of the compounds for double stranded DNA, to which they bind by intercalation. © 2026 The Authors.
UR - http://www.scopus.com/inward/record.url?scp=105039861726&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-105039861726&origin=recordpage
U2 - 10.1016/j.ejmech.2026.118882
DO - 10.1016/j.ejmech.2026.118882
M3 - RGC 21 - Publication in refereed journal
SN - 0223-5234
VL - 315
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 118882
ER -